Table 4 Cost inputs (in USD) in the model
From: Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore
Item | Mean value | Unit | Source | Other remarks |
|---|---|---|---|---|
Cost inputs for diagnosis | ||||
Urology visit | 82 | Per visit | Public healthcare institutions | – |
PSA test | 41 | Per test | Public healthcare institutions | – |
Systematic biopsy | 1108 | Per session | MOH Casemix and Subvention System (2017) | – |
Saturation biopsy | 1563 | Per session | MOH Casemix and Subvention System (2017) | – |
mpMRI | 827 | Per session | Public healthcare institutions | – |
MRI targeted biopsy (inclusive of mpMRI, MRI-US fusion targeted biopsy and systematic biopsy) | 2223 | Per session | Public healthcare institutions | – |
Cost inputs for management and treatment strategy for localized prostate cancer | ||||
Observation | 122 | Per year | Public healthcare institutions | 1 visit to the urologist and PSA testing per year |
Watchful waiting | 163 | Per year | Public healthcare institutions | 1.5 visits to the urologist and PSA testing per year |
Radical prostatectomy | 17,023 | Per episode | MOH Casemix and Subvention System (2017) | Laparoscopic surgery |
Radiotherapy (curative) | 18,382 | 40 treatment sessions | Public healthcare institutions | External beam only, with image-guided radiotherapy |
Androgen deprivation therapy | 439 | 3-monthly | Drug Utilisation Data (2017) | In curative treatment, androgen deprivation therapy included only Luteinizing hormone-releasing hormone (LHRH) agonist. The 3-monthly cost of LHRHa was the weighted mean selling price calculated based on all LHRHa (leuprorelin acetate, goserelin, leuprorelin and triptorelin) in Drug Utilization Data (2017). |
Cost inputs for management and treatment strategy for metastasis and castration-resistant prostate cancer | ||||
Metastatic care - first line therapy | 2194 | Per year | • Survey of local experts • Drug Utilization Data (2017) • MOH Casemix and Subvention System (2017) | – |
Metastatic care – second line therapy | 18,349 | Per year | ||
Treatment for castration-resistant prostate cancer | 26,458 | Per year | ||
Hospice care | 202 | Per day | Assisi Hospice | – |